keyword
MENU ▼
Read by QxMD icon Read
search

deb-tace hcc

keyword
https://www.readbyqxmd.com/read/28706579/conventional-vs-drug-eluting-beads-transarterial-chemoembolization-for-hepatocellular-carcinoma
#1
REVIEW
Jeong Eun Song, Do Young Kim
Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drug-eluting beads (DEBs) have been imposed as novel drug-delivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE...
June 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28685382/safety-and-efficacy-of-transarterial-radioembolisation-in-patients-with-intermediate-or-advanced-stage-hepatocellular-carcinoma-refractory-to-chemoembolisation
#2
Elisabeth G Klompenhouwer, Raphaëla C Dresen, Chris Verslype, Annouschka Laenen, Gert De Hertogh, Christophe M Deroose, Lawrence Bonne, Vincent Vandevaveye, Geert Maleux
INTRODUCTION: Transarterial chemoembolisation (TACE) is the most widely used locoregional treatment for patients with an unresectable hepatocellular carcinoma (HCC). Transarterial radioembolisation (TARE) with yttrium-90 containing microspheres is an emerging interventional treatment that could be complementary or an alternative to TACE. AIM: To evaluate the safety and efficacy of TARE in patients with HCC who are refractory to TACE with drug-eluting beads (DEB-TACE)...
July 6, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28676199/the-art-score-is-not-an-effective-tool-for-optimizing-patient-selection-for-deb-tace-retreatment-a-multicentre-spanish-study
#3
Maria Pipa-Muñiz, Lluis Castells, Sonia Pascual, Javier Fernández-Castroagudín, Iratxe Díez-Miranda, Javier Irurzun, Roberto Díaz-Beveridge, María Senosiaín, Juan Arenas, Manuel de la Mata, Juan Turnes, María Isabel Monge-Romero, Daniel Pérez-Enguix, Javier Bustamante-Schneider, Nora Otegui, Esther Molina-Pérez, José Eduardo Rodríguez-Menéndez, Maria Varela
INTRODUCTION: The appropriate selection of hepatocellular carcinoma (HCC) patients who are eligible for transarterial chemoembolization (TACE) remains a challenge. The ART score has recently been proposed as a method of identifying patients who are eligible or not for a second TACE procedure. OBJECTIVE: To assess the validity of the Assessment for Retreatment with TACE (ART) score in a cohort of patients treated with drug-eluting bead TACE (DEB-TACE). SECONDARY OBJECTIVE: to identify clinical determinants associated with overall survival (OS)...
July 1, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28652049/evaluation-of-texture-analysis-parameter-for-response-prediction-in-patients-with-hepatocellular-carcinoma-undergoing-drug-eluting-bead-transarterial-chemoembolization-deb-tace-using-biphasic-contrast-enhanced-ct-image-data-correlation-with-liver-perfusion
#4
Christopher Kloth, Wolfgang M Thaiss, Rainer Kärgel, Rainer Grimmer, Jan Fritz, Sorin Dumitru Ioanoviciu, Dominik Ketelsen, Konstantin Nikolaou, Marius Horger
RATIONALE AND OBJECTIVES: This study aimed to evaluate the potential role of computed tomography texture analysis (CTTA) of arterial and portal-venous enhancement phase image data for prediction and accurate assessment of response of hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (TACE) by comparison to liver perfusion CT (PCT). MATERIALS AND METHODS: Twenty-eight patients (27 male; mean age 67.2 ± 10.4) with 56 hepatocellular carcinoma-typical liver lesions were included...
June 23, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28648803/sorafenib-in-combination-with-transarterial-chemoembolisation-in-patients-with-unresectable-hepatocellular-carcinoma-tace-2-a-randomised-placebo-controlled-double-blind-phase-3-trial
#5
Tim Meyer, Richard Fox, Yuk Ting Ma, Paul J Ross, Martin W James, Richard Sturgess, Clive Stubbs, Deborah D Stocken, Lucy Wall, Anthony Watkinson, Nigel Hacking, T R Jeffry Evans, Peter Collins, Richard A Hubner, David Cunningham, John Neil Primrose, Philip J Johnson, Daniel H Palmer
BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo. METHODS: We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma...
June 22, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28634515/transarterial-chemoembolization-using-40-%C3%A2%C2%B5m-drug-eluting-beads-for-hepatocellular-carcinoma
#6
Giorgio Greco, Tommaso Cascella, Antonio Facciorusso, Roberto Nani, Rodolfo Lanocita, Carlo Morosi, Marta Vaiani, Giuseppina Calareso, Francesca G Greco, Antonio Ragnanese, Marco A Bongini, Alfonso V Marchianò, Vincenzo Mazzaferro, Carlo Spreafico
AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging...
May 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28629564/computed-tomography-perfusion-imaging-for-monitoring-transarterial-chemoembolization-of-hepatocellular-carcinoma
#7
Herman P Marquez, Amar Karalli, Holger Haubenreisser, Rishi P Mathew, Hatem Alkadhi, Torkel B Brismar, Thomas Henzler, Michael A Fischer
PURPOSE: To prospectively monitor changes in tumor perfusion of hepatocellular carcinoma (HCC) in response to doxorubicin-eluted bead based transarterial chemoembolization (DEB-TACE) using perfusion-CT (P-CT). METHODS AND MATERIALS: 24 patients (54-79 years) undergoing P-CT before and shortly after DEB-TACE of HCC were prospectively included in this dual-center study. Two readers determined arterial-liver-perfusion (ALP, mL/min/100mL), portal-venous-perfusion (PLP, mL/min/100mL) and the hepatic-perfusion-index (HPI, %) by placing matched regions-of-interests within each HCC before and after DEB-TACE...
June 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28500458/occurrence-of-vascular-lake-phenomenon-as-a-predictor-of-improved-tumor-response-in-hcc-patients-that-underwent-deb-tace
#8
Rafael Noronha Cavalcante, Felipe Nasser, Joaquim M Motta-Leal-Filho, Breno B Affonso, Francisco L Galastri, Bruna De Fina, Rodrigo G Garcia, Nelson Wolosker
PURPOSE: To evaluate incidence and predictive factors for the vascular lake phenomenon (VLP), as well as to compare local and overall tumor response in patients with and without VLP induced during DEB-TACE for HCC. METHODS: A total of 200 consecutive patients with 323 HCC nodules underwent first-session DEB-TACE from 2011 to 2014. Patients were divided in two groups, according to the presence of the VLP during DEB-TACE. Pre- and post-treatment imaging studies (CT or MRI) were performed...
July 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28480062/locoregional-and-systemic-therapy-for-hepatocellular-carcinoma
#9
REVIEW
Olumide B Gbolahan, Michael A Schacht, Eric W Beckley, Thomas P LaRoche, Bert H O'Neil, Maximilian Pyko
The management of hepatocellular carcinoma (HCC) remains challenging due to late presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for curative resection and liver transplant. Management in this scenario depends on a number of factors including hepatic function, tumor burden, patency of hepatic vasculature and patients' functional status. Based on these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more advanced disease, sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28442142/predictors-of-therapeutic-effect-of-transarterial-chemoembolisation-using-drug-eluting-beads-for-hepatocellular-carcinoma
#10
Y Asayama, D Okamoto, Y Ushijima, A Nishie, K Ishigami, Y Takayama, N Fujita, H Honda
AIMS: To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between January 2015 and July 2015, tumour variables and angiographic data were collected for 25 patients (49 target lesions) after they had undergone the DEB-TACE procedure for HCC. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Cancer of the Liver at follow-up dynamic computed tomography (CT) performed within 1-4 months after the procedure...
September 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28436630/-clinical-investigation-on-transarterial-chemoembolization-with-indigenous-drug-eluting-beads-in-treatment-of-unresectable-hepatocellular-carcinoma
#11
Gang Chen, Ding Zhang, Yacao Ying, Zhifeng Wang, Wei Tao, Hao Zhu, Jingfeng Zhang, Zhiyi Peng
Objective: To evaluate the efficacy and safety of drug-eluding beads transarterial chemoembolization (DEB-TACE) in treatment of unrecectable hepatocellular carcinoma (HCC). Methods: The clinical data of 42 consecutive HCC patients undergoing TACE were retrospectively analyzed, including 20 cases received conventional TACE (cTACE group) and 22 cases received TACE with epirubicine-loaded microspheres (CalliSpheres (®)) (DEB-TACE group). MRI scans were performed 1 week before and 1, 3 and 6 months after initial therapy...
January 25, 2017: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/28299645/new-concepts-in-embolotherapy-of-hcc
#12
REVIEW
F Pesapane, N Nezami, F Patella, J F Geschwind
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide with rapidly growing incidence rates in the USA and Europe. Despite improving surveillance programs, most patients are diagnosed at intermediate to advanced stages and are no longer amenable to curative therapies, such as ablation, surgical resection and liver transplantation. For such patients, catheter-based image-guided embolotherapies such as transarterial chemoembolization (TACE) represent the standard of care and mainstay therapy, as recommended and endorsed by a variety of national guidelines and staging systems...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28228906/histological-assessment-of-the-efficacy-of-drug-eluting-beads-in-portal-tumor-thrombosis-of-hepatocellular-carcinoma
#13
Yusuke Imai, Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Eiji Takeshita, Masanori Abe, Hiroaki Tanaka, Mie Kurata, Sohei Kitazawa, Yoichi Hiasa
A 58-year-old man was diagnosed with advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT). The tumors were multiple and existed in both lobes. Drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) was performed for the tumors in the left lobe. Embosphere and Hepasphere were selected for embolization of the arterioportal shunt, followed by loaded epirubicin infusion into the left hepatic artery. Computed tomography showed reduction of PVTT. However, liver failure progressed, and the patient died 67 days after DEB-TACE...
March 2017: Radiology case reports
https://www.readbyqxmd.com/read/28170405/treatment-algorithm-based-on-the-multivariate-survival-analyses-in-patients-with-advanced-hepatocellular-carcinoma-treated-with-trans-arterial-chemoembolization
#14
Hasmukh J Prajapati, Hyun S Kim
PURPOSE: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). METHODS: Consecutive unresectable and non-tranplantable patients with advanced HCC, who received DEB TACE were studied. A total of 238 patients (mean age, 62.4yrs) was included in the study. Survivals were analyzed according to different parameters from the time of the 1st DEB TACE...
2017: PloS One
https://www.readbyqxmd.com/read/28166821/deb-tace-for-intermediate-and-advanced-hcc-initial-experience-in-a-brazilian-cancer-center
#15
Jose Hugo Mendes Luz, Paula M Luz, Henrique S Martin, Hugo R Gouveia, Raphal Braz Levigard, Felipe Diniz Nogueira, Bernardo Caetano Rodrigues, Tiago Nepomuceno de Miranda, Marcelo Henrique Mamede
BACKGROUND: According to Barcelona Clinic Liver Cancer classification transarterial chemoembolization is indicated in patients with Hepatocellular Carcinoma in the intermediate stage. Drug-eluting microspheres can absorb and release the chemotherapeutic agent slowly for 14 days after its intra-arterial administration. This type of transarterial chemoembolization approach appears to provide at least equivalent effectiveness with less toxicity. METHODS: This is a prospective, single-center study, which evaluated 21 patients with intermediate and advanced hepatocellular carcinoma who underwent transarterial chemoembolization with drug-eluting microspheres...
February 6, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/27834009/predicting-outcomes-after-chemo-embolization-in-patients-with-advanced-stage-hepatocellular-carcinoma-an-evaluation-of-different-radiologic-response-criteria
#16
Andrew J Gunn, Rahul A Sheth, Brandon Luber, Minh-Huy Huynh, Niranjan R Rachamreddy, Sanjeeva P Kalva
PURPOSE: The purpse of this study was to evaluate the ability of various radiologic response criteria to predict patient outcomes after trans-arterial chemo-embolization with drug-eluting beads (DEB-TACE) in patients with advanced-stage (BCLC C) hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Hospital records from 2005 to 2011 were retrospectively reviewed. Non-infiltrative lesions were measured at baseline and on follow-up scans after DEB-TACE according to various common radiologic response criteria, including guidelines of the World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), the European Association for the Study of the Liver (EASL), and modified RECIST (mRECIST)...
January 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27824665/tumor-enhancement-and-heterogeneity-are-associated-with-treatment-response-to-drug-eluting-bead-chemoembolization-for-hepatocellular-carcinoma
#17
Stephen P Reis, Patrick D Sutphin, Amit G Singal, Richard Grzybowski, Stephen Fisher, Christopher Ball, Yin Xi, Simer Grewal, Sanjeeva P Kalva
PURPOSE: Treatment response to drug-eluting bead chemoembolization (DEB-TACE) is well established for patients with hepatocellular carcinoma (HCC); however, few studies have evaluated tumor imaging characteristics associated with treatment responses. The aim of our study was to identify imaging characteristics associated with treatment responses and overall survival after DEB-TACE of HCC. METHODS: This is a retrospective cohort study of 33 tumors in 32 patients who underwent DEB-TACE for inoperable HCC in a single, large academic medical center...
March 2017: Journal of Computer Assisted Tomography
https://www.readbyqxmd.com/read/27733318/nine-year-experience-of-doxorubicin-eluting-beads-chemoembolization-for-hepatocellular-carcinoma
#18
Alvin Ho-Kwan Cheung, Colin Siu-Chi Lam, Henry Shiu-Cheung Tam, Tan-To Cheung, Roberta Pang, Ronnie Tung-Ping Poon
BACKGROUND: Chemoembolization with doxorubucin-eluting beads (DEB) has been used to treat hepatocellular carcinoma (HCC) since 2007. This study compared the efficacy and survival between transarterial chemoembolization (TACE) with DEB and conventional approach (cTACE) in HCC treatment. METHODS: This retrospective case-control study compared the overall survival and tumor response of HCC patients to cTACE (n=190) and DEB (n=143) by the reassessment of computed tomography and serum alpha-fetoprotein (AFP)...
October 2016: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/27705924/a-mixed-analysis-comparing-nine-minimally-invasive-surgeries-for-unresectable-hepatocellular-carcinoma-patients
#19
Ran Tao, Xiaodan Li, Ruizhi Ran, Zhihua Xiao, Hongyue Zhang, Hongyan Kong, Qiqin Song, Yu Huang, Likui Wang, Jiaquan Huang
Hepatocellular carcinoma (HCC) is usually managed by the transcatheter arterial chemoembolization (TACE). However, this technique has been challenged since severe complications have been observed in clinical practices. As a result, clinicians have started to seek other minimally invasive surgeries with equivalent efficacy. The corresponding surgeries were assessed by the five outcomes: complete response (CR), partial response (PR), stable disease (SD), progression disease (PD) and objective response rate (ORR)...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/27644658/conventional-versus-doxorubicin-eluting-beads-transarterial-chemoembolization-for-unresectable-hepatocellular-carcinoma-a-tertiary-medical-centre-experience-in-malaysia
#20
F Abdul Rahman, J Naidu, C S Ngiu, Y Yaakob, Z Mohamed, H Othman, R Jarmin, M H Elias, N Abdul Hamid, N Mohd Mokhtar, Ra Raja Ali
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer that is frequently diagnosed at an advanced stage. Transarterial chemoembolisation (TACE) is an effective palliative treatment for patients who are not eligible for curative treatment. The two main methods for performing TACE are conventional (c-TACE) or with drug eluting beads (DEB-TACE). We sought to compare survival rates and tumour response between patients undergoing c-TACE and DEB-TACE at our centre. MATERIALS AND METHODS: A retrospective cohort study of patients undergoing either treatment was carried out from January 2009 to December 2014...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
keyword
keyword
109351
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"